Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Spectrum Pharmaceuticals has sold its abbreviated new drug applications for its injectable generic drugs, ondansetron, carboplatin, fludarabine, and mitoxantrone, to Sagent Pharmaceuticals.
Subscribe to our email newsletter
Rajesh Shrotriya, chairman, president and CEO of Spectrum, said: “The sale of these non-core assets provides additional non-dilutive funding which will be used to further fund the advancement of our late stage clinical programs.”